EUCTR2012-002945-40-DE进行中（未招募）1 期
Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months as defined by at least six swollen joints (66 joint count) and at least six tender joints (68 joint count) at Screening and Baseline (Day 1), and either an ESR of >28 mm/hour OR a CRP level >1.0 mg/dL (normal: <0.4 mg/dL) at Screening. Patients must currently be receiving MTX therapy.
- •2. Current treatment for RA on an outpatient basis
- •3. For participants of reproductive potential (males and females), a reliable means of contraception has to be used throughout trial participation and for 6 months following completion or discontinuation from the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 430
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 220
排除标准
- •ACR functional Class IV or wheelchair/bed bound
- •Primary or secondary immunodeficiency (history of, or currently active)
- •History of TB, latent TB, or positive purified protein derivative (PPD)
- •test or interferon gamma-releasing assay (IGRA)
- •Previous treatment with =2 biologic agents. Patients who have
- •received prior treatment with 1 biologic agent >4 months prior to
- •screening may participate in the trial.
- •Previous treatment with adalimumab or adalimumab biosimilar.
- •Current treatment or previous treatment with leflunomide within 8
- •weeks (56 days) prior to Day 1.
- •History of a severe allergic reaction or anaphylactic reaction to a
- •biological agent or history of hypersensitivity to adalimumab or any
- •component of the trial drug
- •History of cancer
- •Evidence of positive serology for HBV or HCV.
- •Platelets <100,000/µL; Leukocyte count <4000/µL; Creatinine
- •clearance <60 mL/min.
- •Receipt of a live/attenuated vaccine within 12 weeks prior to Screening
- •Patients with a significant disease other than RA and/or a significant
- •uncontrolled disease
- •History of, or current, inflammatory joint disease other than RA
- •Diagnosis of juvenile idiopathic arthritis, also known as juvenile RA,
- •and/or RA before age 16
- •Known active infection
- •Patients who are currently participating in another clinical trial or who
- •have been participating in another clinical trial with another
- •investigational drug within a minimum of 12 weeks or five half-lives
- •(whichever is longer) of the drug prior to Day 1.
- •Patients who have previously been randomized in this trial
研究者
相似试验
进行中（未招募）
1 期
BI695501 compared to adalimumab in patients with active rheumatoid arthritisRheumatoid arthritisEUCTR2012-002945-40-ESBoehringer Ingelheim International GmbH600
进行中（未招募）
1 期
BI695501 compared to adalimumab in patients with active rheumatoid arthritisMedDRA version: 17.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2012-002945-40-HUBoehringer Ingelheim International GmbH650
进行中（未招募）
1 期
BI695501 compared to adalimumab in patients with active rheumatoid arthritisMedDRA version: 19.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2012-002945-40-BGBoehringer Ingelheim International GmbH650
进行中（未招募）
1 期
BI695501 compared to adalimumab in patients with active rheumatoid arthritisRheumatoid arthritisEUCTR2012-002945-40-EEBoehringer Ingelheim International GmbH650
进行中（未招募）
1 期
Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2016-000613-79-PLBoehringer Ingelheim International GmbH300